This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Toll-like receptor 4 (TLR4) and TLR7 ligands on nanoparticles for long-lasting immunity	<p>Mouse studies suggest that nanoparticles containing TLR4 and TLR7 ligands as adjuvants could provide long-lasting immunity against infectious diseases. In mice, delivery of a nanoparticle containing TLR4 and TLR7 ligands led to a stronger antigen-specific antibody response, more memory B cell-generating germinal centers and greater protection from H5N1 influenza virus challenge than delivery of a nanoparticle containing either TLR ligand alone. Ongoing work includes using the nanoparticles in animal models of malaria, HIV and dengue infection.</p> <p>SciBX 4(11); doi:10.1038/scibx.2011.325 Published online March 17, 2011</p>	Patent application filed; available for licensing	<p>Kasturi, S.P. <i>et al. Nature</i>; published online Feb. 23, 2011; doi:10.1038/nature09737 Contact: Bali Pulendran, Emory Vaccine Center, Atlanta, Ga. e-mail: bpulend@emory.edu</p>